Novartis shares climbed 0.6% to 100.04 CHF on the SIX Swiss Exchange, showcasing resilience despite a 7.58% revenue decline to 11.32 billion CHF in the second quarter of 2024. The pharmaceutical giant reported earnings per share of 1.44 CHF, a significant improvement from 1.00 CHF in the previous year. Analysts project a full-year 2024 earnings per share of 7.49 USD, with an anticipated dividend of 3.81 USD per share, up from last year's 3.30 CHF. The stock's positive trajectory continues, with a 13.96% year-to-date increase, reflecting investor confidence in Novartis' diverse product portfolio and consistent R&D investments.
Innovative Therapies Drive Growth
Novartis' sustained success can be attributed to its advancements in cutting-edge treatment methods. The company is increasingly focusing on developing cell and gene therapies in areas of high medical need. These forward-thinking approaches could further solidify Novartis' position in the competitive pharmaceutical market and fuel growth in the coming years. The next quarterly results are expected to be released on October 29, 2024, providing further insight into the company's performance and strategic direction.
Ad
Novartis Stock: Buy or Sell? New Novartis Analysis on 15 October Provides the Answer:The latest Novartis figures speak volumes: Urgent action required for Novartis shareholders. Is it worth investing, or should you sell? Find out what to do now in our current free analysis from 15 October.
Novartis: Buy or Sell? Continue reading here ...
